阿森迪斯制药

Ascendis Pharma AS receives a 2-star quantitative star rating, indicating our belief that this share class is a somewhat unattractive choice, and investors should look elsewhere for more fruitful opportunities. The stock currently trades at a 9% premium over our quantitative fair value estimate of $210.82 per share; however, this estimate should be taken with a pinch of salt due to its high uncertainty rating. We require the price/fair value ratio to move a certain amount before the star rating can change. This stability-enhancing buffer is in effect for this stock.

The firm's valuation metrics weaken our fair value estimate. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's enterprise value to EBITDA ratio of 42.8 ranks in the top 20% compared with global peers. This suggests that the value of its enterprise value, or the value of its shares and debt, is a high multiple of the generated EBITDA. We believe this is a sign that shares could be expensive.

The company's unfavorable dividend structure is an additional cause for concern. Dividends represent a stable form of future cash flows returned to shareholders, and low dividend payments can increase the perceived risk of a business. The firm's forward dividend yield of 0%, for example, sits in the bottom 30% compared with peers globally. This could imply a planned dividend cut or relatively high share price, which further promotes our unfavorable price/fair value ratio.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.

The company's narrow economic moat rating suggests it should be able to maintain robust profitability for a decade or longer before competition erodes its advantage. In addition, the company's moderate financial health score is decent and doesn't seriously concern us with regard to financial distress.